Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Monday, 09 December 2019

Change of Director’s Interest Notice

Appendix 3Y – Change of Director’s Interest Notice, is available to download.

Download PDF
 
 

CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and conditions of issue that the following unquoted performance rights have lapsed and forfeited: Class  Number  Exercise  price CUVAK Conditional Performance Rights subject to various performance milestones, issued various dates 40,000 $Nil Consequently, there are now 1,666,460 unlisted conditional performance rights on issue. Download […]

Download PDF
 
 
Thursday, 05 December 2019

Changes of Director’s Interest Notice

  Appendix 3Y Change of Director’s Interest Notice   Download PDF

Download PDF
 
 
Thursday, 05 December 2019

Appendix 3B

  New issue announcement, application for quotation of additional securities and agreement.   Download PDF

Download PDF
 
 
Thursday, 05 December 2019

Changes in Composition to Committeess

  CLINUVEL PHARMACEUTICALS LTD today announced changes to the composition of its Audit & Risk Committee and to its Remuneration Committee. Consequent to his retirement from the Board of Directors, Stan McLiesh will be replaced by Jeffrey Rosenfeld on the Audit & Risk Committee as a voting member. Sue Smith and Karen Agersborg will join […]

Download PDF
 
 
Monday, 02 December 2019

CEO Letter

Dear shareholders, On 8 October 2019, CLINUVEL obtained its first and historic US Food and Drug Administration (FDA) approval, some 39 years since the afamelanotide technology was first discovered in a university laboratory. On this day the intraday share price went up briefly to A$45.88, valuing the Company at A$2.2B; we have seen sell offs […]

Download PDF
 
 
Tuesday, 26 November 2019

Appendix 3X

Initial Director’s Interest Notice. Download PDF

Download PDF
 
 
Tuesday, 26 November 2019

CLINUVEL Appoints Non-Executive Director

CLINUVEL PHARMACEUTICALS LTD today announced the appointment of Professor Jeffrey Rosenfeld as a Non-Executive member of the Group’s Board of Directors. Download PDF

Download PDF
 
 

Melbourne, Australia, 20 November 2019 A MOMENTOUS ACHIEVEMENT Looking at the year in retrospect, I draw a balance on the overall resources it took to achieve one of the greatest successes in Australian pharmaceutical history. At a relatively low expense of under A$139 million, we arrived at a commercial product to serve the needs of […]

Download PDF
 
 
Wednesday, 20 November 2019

Results of Meeting

  Results of Annual General Meeting In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary. […] Download PDF

Download PDF
 
 
Wednesday, 20 November 2019

Managing Director’s AGM Presentation

Melbourne, Australia, 20 November 2019 “We are here today to reflect on a memorable moment, exactly 42 days after the historic FDA approval of SCENESSE® (afamelanotide 16mg), a first for Australia as a New Chemical Entity has come from preclinical stage to market. It marks exactly 39 years since the technology was discovered and first […]

Download PDF
 
 
Thursday, 31 October 2019

Appendix 4C

CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 July to 30 September 2019. Download PDF

Download PDF
 
 

CLINUVEL PHARMACEUTICALS LTD today announced that the Australian Therapeutic Goods Administration (TGA) has granted SCENESSE® (afamelanotide 16 mg) the right to be filed under the priority registration process. This establishes a target scientific evaluation timeframe of 150 working days, calculated from the first day the scientific dossier is accepted. SCENESSE® will be lodged for the […]

Download PDF
 
 

Dearest Shareholders, As the incoming Chair of the Company, in short letters I will try to provide you with updates and inform you about our business.[…] Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from his role as Non-Executive Director and Chair of the Board on 30 November 2019. Non-Executive Director Mr Willem Blijdorp has been elected Chair and will take on the role on 30 November 2019. […] Download PDF

Download PDF
 
Monday, 12 February 2018

CLINUVEL Newsletter - February 2018

12 February 2018 We started this year with limitless optimism and energy, and I attribute this to a foundation of internal changes made over the past 16 months. Our fascinating journey is marred with frequent need …

Download PDF
 
Wednesday, 10 January 2018

Chair Letter to Shareholders

11 January 2018 Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead. The Group will engage in many activities on several continents, and we …

Download PDF
 
Thursday, 07 December 2017

CLINUVEL Newsletter - December 2017

07 December 2017 The CLINUVEL team is looking with much optimism and energy to the start of 2018. I believe the year ahead is one where the Company will make great strides on various fronts: research, …

Download PDF